These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653 [TBL] [Abstract][Full Text] [Related]
32. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. Hou W; Bonkovsky HL World J Gastroenterol; 2013 Nov; 19(44):7836-45. PubMed ID: 24307777 [TBL] [Abstract][Full Text] [Related]
33. Current status of gene therapy for hepatocellular carcinoma, with a focus on gene delivery approaches. Wang X; Tai Z; Zhang W; Gao S Curr Gene Ther; 2015; 15(2):120-41. PubMed ID: 25537775 [TBL] [Abstract][Full Text] [Related]
34. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia. High KA Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929 [TBL] [Abstract][Full Text] [Related]
35. Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectors. Ferla R; Alliegro M; Dell'Anno M; Nusco E; Cullen JM; Smith SN; Wolfsberg TG; O'Donnell P; Wang P; Nguyen AD; Chandler RJ; Chen Z; Burgess SM; Vite CH; Haskins ME; Venditti CP; Auricchio A Mol Ther Methods Clin Dev; 2021 Mar; 20():247-257. PubMed ID: 33473358 [TBL] [Abstract][Full Text] [Related]
36. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793 [TBL] [Abstract][Full Text] [Related]
37. The complex, confusing and poorly understood immune responses to AAV-mediated gene transfer in haemophilia-Is more or less immunosuppression required? Tuddenham EGD; Foster GR J Viral Hepat; 2024 Apr; 31 Suppl 1():21-25. PubMed ID: 38606938 [TBL] [Abstract][Full Text] [Related]
38. Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector. Della Peruta M; Badar A; Rosales C; Chokshi S; Kia A; Nathwani D; Galante E; Yan R; Arstad E; Davidoff AM; Williams R; Lythgoe MF; Nathwani AC Hum Gene Ther; 2015 Feb; 26(2):94-103. PubMed ID: 25569358 [TBL] [Abstract][Full Text] [Related]
39. HCV-related liver cancer in people with haemophilia. Meijer K; Haagsma EB Haemophilia; 2012 Jan; 18(1):17-24. PubMed ID: 21651676 [TBL] [Abstract][Full Text] [Related]
40. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model. Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]